NO792335L - Legemiddel-retardform med uopploeselige, poroese diffusjonsovertrekk - Google Patents

Legemiddel-retardform med uopploeselige, poroese diffusjonsovertrekk

Info

Publication number: NO792335L
Authority: NO; Norway
Prior art keywords: active substance; tablets; coating; acid; retarded
Prior art date: 1978-07-15

Application number

NO792335A

Other languages

English (en)

Norwegian (no)

Inventor

Herbert Stricker

Bernhard Freund

Heribert Harwalik

Karl Ludwig Rominger

Siegfried Darda

Volkmar Haeselbarth

Dietrich Arndts

Wolf Dietrich Bechtel

Gerhard Bozler

Rolf Brickl

Peter Gruber

Original Assignee

Boehringer Sohn Ingelheim

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1978-07-15

Filing date

1979-07-13

Publication date

1980-01-16

1978-07-15 Priority claimed from DE19782831164 external-priority patent/DE2831164A1/de

1978-08-19 Priority claimed from DE19782836357 external-priority patent/DE2836357A1/de

1978-08-19 Priority claimed from DE19782836356 external-priority patent/DE2836356A1/de

1978-08-19 Priority claimed from DE19782836419 external-priority patent/DE2836419A1/de

1978-08-19 Priority claimed from DE19782836387 external-priority patent/DE2836387A1/de

1978-08-19 Priority claimed from DE19782836358 external-priority patent/DE2836358A1/de

1978-08-19 Priority claimed from DE19782836388 external-priority patent/DE2836388A1/de

1978-08-19 Priority claimed from DE19782836355 external-priority patent/DE2836355A1/de

1978-08-19 Priority claimed from DE19782836447 external-priority patent/DE2836447A1/de

1979-07-13 Application filed by Boehringer Sohn Ingelheim filed Critical Boehringer Sohn Ingelheim

1980-01-16 Publication of NO792335L publication Critical patent/NO792335L/no

Links

238000009792 diffusion process Methods 0.000 title claims description 20
239000013543 active substance Substances 0.000 claims description 74
238000000576 coating method Methods 0.000 claims description 57
239000011248 coating agent Substances 0.000 claims description 49
238000004519 manufacturing process Methods 0.000 claims description 37
239000000126 substance Substances 0.000 claims description 34
239000007921 spray Substances 0.000 claims description 25
239000002253 acid Substances 0.000 claims description 18
230000002378 acidificating effect Effects 0.000 claims description 17
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
229920000642 polymer Polymers 0.000 claims description 9
150000003839 salts Chemical class 0.000 claims description 9
150000007513 acids Chemical class 0.000 claims description 6
238000004090 dissolution Methods 0.000 claims description 5
239000002904 solvent Substances 0.000 claims description 4
229940079593 drug Drugs 0.000 claims description 3
239000003814 drug Substances 0.000 claims description 3
230000035699 permeability Effects 0.000 claims description 3
230000003111 delayed effect Effects 0.000 claims description 2
239000003826 tablet Substances 0.000 description 122
238000002360 preparation method Methods 0.000 description 36
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 27
239000002775 capsule Substances 0.000 description 20
239000000203 mixture Substances 0.000 description 18
239000000546 pharmaceutical excipient Substances 0.000 description 18
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 17
ADYPXRFPBQGGAH-UMYZUSPBSA-N dihydroergotamine mesylate Chemical compound CS(O)(=O)=O.C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2[C@@H](C=3C=CC=C4NC=C(C=34)C2)C1)C)C1=CC=CC=C1 ADYPXRFPBQGGAH-UMYZUSPBSA-N 0.000 description 16
239000002202 Polyethylene glycol Substances 0.000 description 14
229920001223 polyethylene glycol Polymers 0.000 description 14
238000011049 filling Methods 0.000 description 13
229960002768 dipyridamole Drugs 0.000 description 12
IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 12
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 12
238000002156 mixing Methods 0.000 description 12
239000001856 Ethyl cellulose Substances 0.000 description 11
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 11
230000000694 effects Effects 0.000 description 11
229920001249 ethyl cellulose Polymers 0.000 description 11
235000019325 ethyl cellulose Nutrition 0.000 description 11
239000004480 active ingredient Substances 0.000 description 10
239000012736 aqueous medium Substances 0.000 description 10
238000007906 compression Methods 0.000 description 10
230000006835 compression Effects 0.000 description 10
238000001035 drying Methods 0.000 description 10
239000007903 gelatin capsule Substances 0.000 description 10
238000003825 pressing Methods 0.000 description 10
LSLYOANBFKQKPT-DIFFPNOSSA-N 5-[(1r)-1-hydroxy-2-[[(2r)-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]benzene-1,3-diol Chemical compound C([C@@H](C)NC[C@H](O)C=1C=C(O)C=C(O)C=1)C1=CC=C(O)C=C1 LSLYOANBFKQKPT-DIFFPNOSSA-N 0.000 description 9
GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 9
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 9
VCVQSRCYSKKPBA-UHFFFAOYSA-N bunitrolol Chemical compound CC(C)(C)NCC(O)COC1=CC=CC=C1C#N VCVQSRCYSKKPBA-UHFFFAOYSA-N 0.000 description 9
229950008581 bunitrolol Drugs 0.000 description 9
229960002896 clonidine Drugs 0.000 description 9
238000005538 encapsulation Methods 0.000 description 9
229960001022 fenoterol Drugs 0.000 description 9
239000008240 homogeneous mixture Substances 0.000 description 9
229920000036 polyvinylpyrrolidone Polymers 0.000 description 9
239000001267 polyvinylpyrrolidone Substances 0.000 description 9
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 9
239000002966 varnish Substances 0.000 description 9
239000007950 delayed release tablet Substances 0.000 description 8
239000002360 explosive Substances 0.000 description 8
SQVIAVUSQAWMKL-UHFFFAOYSA-N 3-[2-(ethylamino)-1-hydroxyethyl]phenol Chemical compound CCNCC(O)C1=CC=CC(O)=C1 SQVIAVUSQAWMKL-UHFFFAOYSA-N 0.000 description 7
229920002261 Corn starch Polymers 0.000 description 7
229960004695 etilefrine Drugs 0.000 description 7
235000011389 fruit/vegetable juice Nutrition 0.000 description 7
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 7
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 7
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 7
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 7
230000000968 intestinal effect Effects 0.000 description 7
239000008101 lactose Substances 0.000 description 7
238000009481 moist granulation Methods 0.000 description 7
239000011975 tartaric acid Substances 0.000 description 7
235000002906 tartaric acid Nutrition 0.000 description 7
DKSZLDSPXIWGFO-BLOJGBSASA-N (4r,4ar,7s,7ar,12bs)-9-methoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ol;phosphoric acid;hydrate Chemical compound O.OP(O)(O)=O.OP(O)(O)=O.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC DKSZLDSPXIWGFO-BLOJGBSASA-N 0.000 description 6
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
238000006243 chemical reaction Methods 0.000 description 6
229960004415 codeine phosphate Drugs 0.000 description 6
239000008120 corn starch Substances 0.000 description 6
238000005469 granulation Methods 0.000 description 6
230000003179 granulation Effects 0.000 description 6
235000019359 magnesium stearate Nutrition 0.000 description 6
XQYZDYMELSJDRZ-UHFFFAOYSA-N papaverine Chemical compound C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 XQYZDYMELSJDRZ-UHFFFAOYSA-N 0.000 description 6
KBAUFVUYFNWQFM-UHFFFAOYSA-N Doxylamine succinate Chemical compound OC(=O)CCC(O)=O.C=1C=CC=NC=1C(C)(OCCN(C)C)C1=CC=CC=C1 KBAUFVUYFNWQFM-UHFFFAOYSA-N 0.000 description 5
229960005008 doxylamine succinate Drugs 0.000 description 5
230000002035 prolonged effect Effects 0.000 description 5
VLPIATFUUWWMKC-SNVBAGLBSA-N (2r)-1-(2,6-dimethylphenoxy)propan-2-amine Chemical compound C[C@@H](N)COC1=C(C)C=CC=C1C VLPIATFUUWWMKC-SNVBAGLBSA-N 0.000 description 4
JIVPVXMEBJLZRO-CQSZACIVSA-N 2-chloro-5-[(1r)-1-hydroxy-3-oxo-2h-isoindol-1-yl]benzenesulfonamide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC([C@@]2(O)C3=CC=CC=C3C(=O)N2)=C1 JIVPVXMEBJLZRO-CQSZACIVSA-N 0.000 description 4
229920000623 Cellulose acetate phthalate Polymers 0.000 description 4
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 4
229940081734 cellulose acetate phthalate Drugs 0.000 description 4
229960001523 chlortalidone Drugs 0.000 description 4
239000002552 dosage form Substances 0.000 description 4
210000001035 gastrointestinal tract Anatomy 0.000 description 4
229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 4
229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 4
LOUPRKONTZGTKE-LHHVKLHASA-N quinidine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-LHHVKLHASA-N 0.000 description 4
230000009467 reduction Effects 0.000 description 4
229930008281 A03AD01 - Papaverine Natural products 0.000 description 3
JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 3
239000003416 antiarrhythmic agent Substances 0.000 description 3
230000036772 blood pressure Effects 0.000 description 3
230000001419 dependent effect Effects 0.000 description 3
230000002349 favourable effect Effects 0.000 description 3
229960002003 hydrochlorothiazide Drugs 0.000 description 3
229960001361 ipratropium bromide Drugs 0.000 description 3
KEWHKYJURDBRMN-ZEODDXGYSA-M ipratropium bromide hydrate Chemical compound O.[Br-].O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 KEWHKYJURDBRMN-ZEODDXGYSA-M 0.000 description 3
MOYKHGMNXAOIAT-JGWLITMVSA-N isosorbide dinitrate Chemical compound [O-][N+](=O)O[C@H]1CO[C@@H]2[C@H](O[N+](=O)[O-])CO[C@@H]21 MOYKHGMNXAOIAT-JGWLITMVSA-N 0.000 description 3
229960000201 isosorbide dinitrate Drugs 0.000 description 3
229920000609 methyl cellulose Polymers 0.000 description 3
239000001923 methylcellulose Substances 0.000 description 3
235000010981 methylcellulose Nutrition 0.000 description 3
229960003404 mexiletine Drugs 0.000 description 3
229960001789 papaverine Drugs 0.000 description 3
239000002245 particle Substances 0.000 description 3
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
229920000168 Microcrystalline cellulose Polymers 0.000 description 2
FNYLWPVRPXGIIP-UHFFFAOYSA-N Triamterene Chemical compound NC1=NC2=NC(N)=NC(N)=C2N=C1C1=CC=CC=C1 FNYLWPVRPXGIIP-UHFFFAOYSA-N 0.000 description 2
230000009471 action Effects 0.000 description 2
230000000202 analgesic effect Effects 0.000 description 2
230000003288 anthiarrhythmic effect Effects 0.000 description 2
229940030600 antihypertensive agent Drugs 0.000 description 2
239000002220 antihypertensive agent Substances 0.000 description 2
LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 2
OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
HESHRHUZIWVEAJ-JGRZULCMSA-N dihydroergotamine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2[C@@H](C3=CC=CC4=NC=C([C]34)C2)C1)C)C1=CC=CC=C1 HESHRHUZIWVEAJ-JGRZULCMSA-N 0.000 description 2
229960004704 dihydroergotamine Drugs 0.000 description 2
238000009826 distribution Methods 0.000 description 2
208000002173 dizziness Diseases 0.000 description 2
230000002496 gastric effect Effects 0.000 description 2
239000008187 granular material Substances 0.000 description 2
150000003840 hydrochlorides Chemical class 0.000 description 2
-1 hydroxy- Chemical class 0.000 description 2
230000006872 improvement Effects 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
239000007788 liquid Substances 0.000 description 2
235000019813 microcrystalline cellulose Nutrition 0.000 description 2
239000008108 microcrystalline cellulose Substances 0.000 description 2
229940016286 microcrystalline cellulose Drugs 0.000 description 2
230000036470 plasma concentration Effects 0.000 description 2
229960001404 quinidine Drugs 0.000 description 2
RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 2
235000012239 silicon dioxide Nutrition 0.000 description 2
239000007944 soluble tablet Substances 0.000 description 2
238000005507 spraying Methods 0.000 description 2
239000000725 suspension Substances 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
229960001288 triamterene Drugs 0.000 description 2
NNJPGOLRFBJNIW-HNNXBMFYSA-N (-)-demecolcine Chemical compound C1=C(OC)C(=O)C=C2[C@@H](NC)CCC3=CC(OC)=C(OC)C(OC)=C3C2=C1 NNJPGOLRFBJNIW-HNNXBMFYSA-N 0.000 description 1
BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
GJHKWLSRHNWTAN-UHFFFAOYSA-N 1-ethoxy-4-(4-pentylcyclohexyl)benzene Chemical compound C1CC(CCCCC)CCC1C1=CC=C(OCC)C=C1 GJHKWLSRHNWTAN-UHFFFAOYSA-N 0.000 description 1
WYOWAXDWPIYPNZ-UHFFFAOYSA-M 5-[1-hydroxy-2-[1-(4-hydroxyphenyl)propan-2-ylamino]ethyl]benzene-1,3-diol;(8-methyl-8-propan-2-yl-8-azoniabicyclo[3.2.1]octan-3-yl) 3-hydroxy-2-phenylpropanoate;bromide;hydrobromide Chemical compound Br.[Br-].C=1C(O)=CC(O)=CC=1C(O)CNC(C)CC1=CC=C(O)C=C1.CC(C)[N+]1(C)C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 WYOWAXDWPIYPNZ-UHFFFAOYSA-M 0.000 description 1
BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 description 1
HBLPYIOKPJVFQW-UHFFFAOYSA-N 6-ethyl-4,5,7,8-tetrahydro-[1,3]oxazolo[4,5-d]azepin-2-amine;hydron;dichloride Chemical compound Cl.Cl.C1CN(CC)CCC2=C1OC(N)=N2 HBLPYIOKPJVFQW-UHFFFAOYSA-N 0.000 description 1
NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
229920003134 Eudragit® polymer Polymers 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
235000019759 Maize starch Nutrition 0.000 description 1
CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
206010028813 Nausea Diseases 0.000 description 1
101100442582 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) spe-1 gene Proteins 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
229920002845 Poly(methacrylic acid) Polymers 0.000 description 1
241000404546 Soliva Species 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
239000000150 Sympathomimetic Substances 0.000 description 1
208000001871 Tachycardia Diseases 0.000 description 1
150000008043 acidic salts Chemical class 0.000 description 1
230000006978 adaptation Effects 0.000 description 1
238000007605 air drying Methods 0.000 description 1
BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
150000008064 anhydrides Chemical class 0.000 description 1
230000003042 antagnostic effect Effects 0.000 description 1
230000003276 anti-hypertensive effect Effects 0.000 description 1
230000004888 barrier function Effects 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
230000036765 blood level Effects 0.000 description 1
208000006218 bradycardia Diseases 0.000 description 1
230000036471 bradycardia Effects 0.000 description 1
239000000337 buffer salt Substances 0.000 description 1
239000002371 cardiac agent Substances 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
230000008859 change Effects 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
239000008199 coating composition Substances 0.000 description 1
229960004126 codeine Drugs 0.000 description 1
238000004040 coloring Methods 0.000 description 1
230000007423 decrease Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
FHHZOYXKOICLGH-UHFFFAOYSA-N dichloromethane;ethanol Chemical compound CCO.ClCCl FHHZOYXKOICLGH-UHFFFAOYSA-N 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
206010013781 dry mouth Diseases 0.000 description 1
239000000975 dye Substances 0.000 description 1
239000003792 electrolyte Substances 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
LSLYOANBFKQKPT-UHFFFAOYSA-N fenoterol Chemical compound C=1C(O)=CC(O)=CC=1C(O)CNC(C)CC1=CC=C(O)C=C1 LSLYOANBFKQKPT-UHFFFAOYSA-N 0.000 description 1
229940023084 fenoterol / ipratropium Drugs 0.000 description 1
239000007888 film coating Substances 0.000 description 1
238000009501 film coating Methods 0.000 description 1
235000013305 food Nutrition 0.000 description 1
239000000576 food coloring agent Substances 0.000 description 1
230000037406 food intake Effects 0.000 description 1
239000001087 glyceryl triacetate Substances 0.000 description 1
235000013773 glyceryl triacetate Nutrition 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
229940099438 hydrochlorothiazide / triamterene Drugs 0.000 description 1
OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
238000001802 infusion Methods 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
239000004922 lacquer Substances 0.000 description 1
239000004310 lactic acid Substances 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
239000001630 malic acid Substances 0.000 description 1
235000011090 malic acid Nutrition 0.000 description 1
239000000463 material Substances 0.000 description 1
238000000034 method Methods 0.000 description 1
VLPIATFUUWWMKC-UHFFFAOYSA-N mexiletine Chemical compound CC(N)COC1=C(C)C=CC=C1C VLPIATFUUWWMKC-UHFFFAOYSA-N 0.000 description 1
230000004899 motility Effects 0.000 description 1
238000000465 moulding Methods 0.000 description 1
230000008693 nausea Effects 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
230000000414 obstructive effect Effects 0.000 description 1
239000008188 pellet Substances 0.000 description 1
230000007903 penetration ability Effects 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
239000004014 plasticizer Substances 0.000 description 1
229960004482 quinidine sulfate Drugs 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
208000023504 respiratory system disease Diseases 0.000 description 1
239000011877 solvent mixture Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008107 starch Substances 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
229910021653 sulphate ion Inorganic materials 0.000 description 1
230000001975 sympathomimetic effect Effects 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
238000009492 tablet coating Methods 0.000 description 1
239000002700 tablet coating Substances 0.000 description 1
230000006794 tachycardia Effects 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
229940125712 tocolytic agent Drugs 0.000 description 1
239000003675 tocolytic agent Substances 0.000 description 1
238000012546 transfer Methods 0.000 description 1
229960002622 triacetin Drugs 0.000 description 1
229940124549 vasodilator Drugs 0.000 description 1
239000003071 vasodilator agent Substances 0.000 description 1
229920003169 water-soluble polymer Polymers 0.000 description 1
238000005550 wet granulation Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Preparation (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

NO792335A 1978-07-15 1979-07-13 Legemiddel-retardform med uopploeselige, poroese diffusjonsovertrekk NO792335L (no)

Applications Claiming Priority (10)

Application Number	Priority Date	Filing Date	Title
DE19782831164 DE2831164A1 (de)	1978-07-15	1978-07-15	Arzneimittel-retardform mit unloeslichen poroesen diffusionshuellen
DE19782836357 DE2836357A1 (de)	1978-08-19	1978-08-19	Neue fenoterol-retardform
DE19782836356 DE2836356A1 (de)	1978-08-19	1978-08-19	Neue clonidin-retardform
DE19782836419 DE2836419A1 (de)	1978-08-19	1978-08-19	Neue chinidin-retardform
DE19782836387 DE2836387A1 (de)	1978-08-19	1978-08-19	Retardform fuer einen blutdrucksenkenden und antanginoes wirkenden stoff
DE19782836358 DE2836358A1 (de)	1978-08-19	1978-08-19	Neue etilefrin-retardform
DE19782836388 DE2836388A1 (de)	1978-08-19	1978-08-19	Neue codein-retardform
DE19782836355 DE2836355A1 (de)	1978-08-19	1978-08-19	Neue mexiletin-retardform
DE19782836447 DE2836447A1 (de)	1978-08-19	1978-08-19	Neue bunitrolol-retardform
DE2905602		1979-02-14

Publications (1)

Publication Number	Publication Date
NO792335L true NO792335L (no)	1980-01-16

Family

ID=27579139

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO792335A NO792335L (no)	1978-07-15	1979-07-13	Legemiddel-retardform med uopploeselige, poroese diffusjonsovertrekk

Country Status (18)

Country	Link
US (3)	US4361546A (de)
AU (1)	AU4894779A (de)
BE (1)	BE877706A (de)
CA (1)	CA1126156A (de)
DD (1)	DD146547A5 (de)
DK (1)	DK296979A (de)
FI (1)	FI792204A (de)
FR (1)	FR2430766A1 (de)
GB (1)	GB2025227B (de)
GR (1)	GR71195B (de)
IL (1)	IL57796A0 (de)
IT (1)	IT1116877B (de)
LU (1)	LU81503A1 (de)
NL (1)	NL7905484A (de)
NO (1)	NO792335L (de)
PT (1)	PT69922A (de)
SE (1)	SE7906119L (de)
ZA (1)	ZA793542B (de)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DD146547A5 (de) *	1978-07-15	1981-02-18	Boehringer Sohn Ingelheim	Arzneimittel-retardform mit unloeslichen poroesen diffusionshuellen
US4411882A (en)	1978-12-21	1983-10-25	Sandoz Ltd.	Galenical compositions
FR2470599A1 (fr) *	1979-12-07	1981-06-12	Panoz Donald	Perfectionnements apportes aux procedes de preparation de formes galeniques a action retard et a liberation programmee et formes galeniques de medicaments ainsi obtenus
DE3000979A1 (de)	1980-01-12	1981-07-23	Dr. Karl Thomae Gmbh, 7950 Biberach	Neue dipyridamol-retardformen und verfahren zu ihrer herstellung
FR2477015A1 (fr) *	1980-03-03	1981-09-04	Fabre Sa Pierre	Composition pharmaceutique a base d'un alcaloide de l'ergot de seigle, a activite regulatrice sur le tonus vasculaire
DE3124090A1 (de) *	1981-06-19	1983-01-05	Dr. Karl Thomae Gmbh, 7950 Biberach	Neue orale dipyridamolformen
DE3126703A1 (de)	1981-07-07	1983-01-27	Dr. Karl Thomae Gmbh, 7950 Biberach	Bromhexin-retardform und verfahren zu ihrer herstellung
US4415547A (en)	1982-06-14	1983-11-15	Sterling Drug Inc.	Sustained-release pharmaceutical tablet and process for preparation thereof
US4704284A (en) *	1982-08-12	1987-11-03	Pfizer Inc.	Long-acting matrix tablet formulations
DE3237575A1 (de) *	1982-10-09	1984-04-12	Dr. Karl Thomae Gmbh, 7950 Biberach	Neue orale mopidamolformen
DE3306250A1 (de) *	1983-02-23	1984-08-23	Basf Ag, 6700 Ludwigshafen	Sphaerische einkristalle fuer pharmazeutische zwecke
IE55745B1 (en) *	1983-04-06	1991-01-02	Elan Corp Plc	Sustained absorption pharmaceutical composition
KR880002139B1 (ko) *	1983-04-08	1988-10-17	베링거 인겔하임 리미티드	경구 투여용 정제의 제조방법
US4690682A (en) *	1983-04-15	1987-09-01	Damon Biotech, Inc.	Sustained release
US4789516A (en) *	1983-04-15	1988-12-06	Damon Biotech, Inc	Production of sustained released system
DE3314003A1 (de) *	1983-04-18	1984-10-18	Boehringer Ingelheim KG, 6507 Ingelheim	Teilbare tablette mit verzoegerter wirkstofffreigabe und verfahren zu deren herstellung
USRE33994E (en) *	1983-08-16	1992-07-14	Burroughs Wellcome Co.	Pharmaceutical delivery system
GB8322007D0 (en) *	1983-08-16	1983-09-21	Wellcome Found	Pharmaceutical delivery system
JPS6051106A (ja) *	1983-08-31	1985-03-22	Yamanouchi Pharmaceut Co Ltd	塩酸アモスラロ−ル持続性製剤
IE56459B1 (en) *	1983-12-21	1991-08-14	Elan Corp Ltd	Controlled absorption pharmaceutical formulation
US5364620A (en) *	1983-12-22	1994-11-15	Elan Corporation, Plc	Controlled absorption diltiazem formulation for once daily administration
US4917899A (en) *	1983-12-22	1990-04-17	Elan Corporation Plc	Controlled absorption diltiazem formulation
IE56999B1 (en) *	1983-12-22	1992-03-11	Elan Corp Plc	Pharmaceutical formulation
DK62184D0 (da) *	1984-02-10	1984-02-10	Benzon As Alfred	Diffusionsovertrukket polydepotpraeparat
IE59287B1 (en) *	1984-02-10	1994-02-09	Benzon Pharma As	Diffusion coated multiple-units dosage form
GB8414221D0 (en) *	1984-06-04	1984-07-11	Sterwin Ag	Unit dosage form
GB8414220D0 (en) *	1984-06-04	1984-07-11	Sterwin Ag	Medicaments in unit dose form
DE3486409T2 (de) *	1984-08-17	1996-04-25	Wellcome Found	Zusammensetzung zur kontrollierten Abgabe eines Wirkstoffs.
US5229132A (en) *	1985-02-22	1993-07-20	Grimberg Georges Serge	Non-absorbable gastrointestinal medicament provided for treating the two levels of the digestive tract at the same time
US4666704A (en) *	1985-05-24	1987-05-19	International Minerals & Chemical Corp.	Controlled release delivery system for macromolecules
CH666405A5 (de) *	1985-06-24	1988-07-29	Ciba Geigy Ag	Feste, haltbare darreichungsformen mit elastischem filmueberzug.
EP0209071B2 (de) *	1985-07-10	1998-07-15	Novartis AG	Kontaktlinsenpflegesatz
US4898733A (en) *	1985-11-04	1990-02-06	International Minerals & Chemical Corp.	Layered, compression molded device for the sustained release of a beneficial agent
US4826688A (en) *	1985-11-13	1989-05-02	501 Elan Corporation PLC.	Controlled absorption pharmaceutical formulation
US4892742A (en) *	1985-11-18	1990-01-09	Hoffmann-La Roche Inc.	Controlled release compositions with zero order release
US4717567A (en) *	1985-11-25	1988-01-05	Eastman Kodak Company	Rumen-stable pellets
JPH0776172B2 (ja) *	1986-04-16	1995-08-16	藤沢薬品工業株式会社	マトリツクス錠
DE3622487A1 (de) *	1986-07-02	1988-01-14	Schering Ag	Arzneimittel mit verzoegerter wirkstoffabgabe
GB8616669D0 (en) *	1986-07-09	1986-08-13	Merk Sharpe & Dohme Ltd	Pharmaceutical compositions
GB8618811D0 (en) *	1986-08-01	1986-09-10	Approved Prescription Services	Sustained release ibuprofen formulation
DE3642648A1 (de) *	1986-12-13	1988-06-23	Boehringer Ingelheim Kg	Verwendung von 6-allyl-2-amino-5,6,7,8-tetrahydro-4h-thiazolo-(5,4-d)azepin zur freisetzung von wachstumshormon
SE460945B (sv) *	1987-01-15	1989-12-11	Lejus Medical Ab	En multipel-unit-dos komposition av furosemid
US5057317A (en) *	1987-03-24	1991-10-15	Chugai Seiyaku Kabushiki Kaisha	Slow-release pharmaceutical agent
US4957494A (en) *	1987-06-25	1990-09-18	Alza Corporation	Multi-layer delivery system
US5499979A (en) *	1987-06-25	1996-03-19	Alza Corporation	Delivery system comprising kinetic forces
US5110597A (en) *	1987-06-25	1992-05-05	Alza Corporation	Multi-unit delivery system
US5023088A (en) *	1987-06-25	1991-06-11	Alza Corporation	Multi-unit delivery system
US4874388A (en) *	1987-06-25	1989-10-17	Alza Corporation	Multi-layer delivery system
US5219621A (en) *	1987-10-16	1993-06-15	Elan Corporation, Plc	Methods of treatment with diltiazem formulations
US4851226A (en) *	1987-11-16	1989-07-25	Mcneil Consumer Products Company	Chewable medicament tablet containing means for taste masking
US4804540A (en) *	1987-12-16	1989-02-14	G. D. Searle & Co.	Process for preparing the combination products of triamterene and hydrochlorothiazide
FI101344B (fi) †	1988-03-31	1998-06-15	Tanabe Seiyaku Co	Menetelmä valmistaa valmiste, josta kontrolloidusti vapautuu farmaseut tisesti aktiivista ainetta
GB8813032D0 (en) *	1988-06-02	1988-07-06	Boehringer Ingelheim Int	Antiviral pharmaceutical composition
GB8913889D0 (en) *	1989-06-16	1989-08-02	May & Baker Ltd	New compositions of matter
NZ234227A (en) *	1989-06-30	1991-08-27	Smithkline Beecham Corp	Delayed release dosage form
JPH03145418A (ja) *	1989-10-27	1991-06-20	Sumitomo Pharmaceut Co Ltd	塩基性薬物塩酸塩の徐放性製剤
CH678920A5 (de) *	1989-11-14	1991-11-29	Gergely Gerhard
US5188836A (en) *	1990-07-27	1993-02-23	Warner-Lambert Company	Sustained release formulations
MX9200700A (es) *	1991-02-27	1992-08-01	Boehringer Ingelheim Kg	Solucion de laca retardante para preparaciones farmaceuticas.
US5760093A (en) *	1991-02-27	1998-06-02	Boehringer Ingelheim Kg	Halohydrocarbon-free delayed release lacquer solution for pharmaceutical preparation
ATE120089T1 (de) *	1991-05-20	1995-04-15	Marion Laboratories Inc	Mehrschichtige zubereitung mit kontrollierter freisetzung.
US5407686A (en) *	1991-11-27	1995-04-18	Sidmak Laboratories, Inc.	Sustained release composition for oral administration of active ingredient
US5436011A (en) *	1993-04-16	1995-07-25	Bristol-Myers Squibb Company	Solid pharmaceutical dosage form and a method for reducing abrasion
US6746691B2 (en)	1993-09-20	2004-06-08	Kos Pharmaceuticals, Inc.	Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics
US6818229B1 (en)	1993-09-20	2004-11-16	Kos Pharmaceuticals, Inc.	Intermediate release nicotinic acid compositions for treating hyperlipidemia
US6129930A (en) *	1993-09-20	2000-10-10	Bova; David J.	Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night
US6080428A (en)	1993-09-20	2000-06-27	Bova; David J.	Nicotinic acid compositions for treating hyperlipidemia and related methods therefor
US6676967B1 (en)	1993-09-20	2004-01-13	Kos Pharmaceuticals, Inc.	Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia
US5484607A (en) *	1993-10-13	1996-01-16	Horacek; H. Joseph	Extended release clonidine formulation
UA65607C2 (uk)	1998-03-04	2004-04-15	Орто-Макнейл Фармацевтикал, Інк.	Фармацевтична композиція (варіанти) та спосіб її приготування
DE19820529A1 (de)	1998-05-08	1999-11-11	Lohmann Therapie Syst Lts	Wirkstoff enthaltende orale und mucosale Zubereitung mit steuerbarer Wirkstofffreisetzung und ihre Verwendung
US6669954B2 (en)	2000-01-25	2003-12-30	John R. Crison	Controlled release of drugs
US20030181488A1 (en) *	2002-03-07	2003-09-25	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
WO2006100281A2 (en)	2005-03-22	2006-09-28	Losan Pharma Gmbh	Solubilized ibuprofen
IL169678A (en)	2005-07-14	2010-11-30	Innova Sa	Sweetener compositions
AU2007211091B8 (en) *	2006-01-27	2013-08-29	Adare Pharmaceuticals, Inc.	Drug delivery systems comprising weakly basic selective serotonin 5-HT3 blocking agent and organic acids
RU2428176C2 (ru) *	2006-01-27	2011-09-10	Юранд, Инк.	Системы доставки лекарственного средства, содержащие слабоосновные лекарственные средства и органические кислоты
DE602006000819T2 (de) *	2006-02-09	2009-04-09	Teva Pharmaceutical Industries Ltd.	Dipyridamol enthaltende Zusammensetzungen mit verlängerter Freisetzung und Verfahren zu deren Herstellung
US20100172991A1 (en) *	2007-06-08	2010-07-08	Henry Joseph Horacek	Extended Release Formulation and Methods of Treating Adrenergic Dysregulation
JP2010529142A (ja) *	2007-06-08	2010-08-26	アドレネクス・ファーマシューティカルズ，インコーポレイテッド	アドレナリン調節異常症を治療する徐放性の製剤および方法
EP2187873B1 (de)	2007-08-13	2018-07-25	Abuse Deterrent Pharmaceutical Llc	Gegen missbrauch gesicherte arzneimittel, anwendungsverfahren und herstellungsverfahren
US20090196935A1 (en) *	2008-02-01	2009-08-06	Ahmed Salah U	Pharmaceutical Capsules Comprising Extended Release Dipyridamole Pellets
US8133506B2 (en) *	2008-03-12	2012-03-13	Aptalis Pharmatech, Inc.	Drug delivery systems comprising weakly basic drugs and organic acids
US20100080846A1 (en) *	2008-09-25	2010-04-01	Avshalom Ben-Menachem	Dipyridamole and acetylsalicylic acid formulations and process for preparing same
US20110003005A1 (en) *	2009-07-06	2011-01-06	Gopi Venkatesh	Methods of Treating PDNV and PONV with Extended Release Ondansetron Compositions
IL208594A (en)	2010-10-10	2014-11-30	Innova Sa	The sweet preparations containing an octopus melting mixture from combination cellulose and sweetening sugar and methods for making them
US8999393B1 (en)	2013-01-09	2015-04-07	Edgemont Pharmaceuticals Llc	Sustained release formulations of lorazepam
US20140275038A1 (en)	2013-03-15	2014-09-18	Inspirion Delivery Technologies, Llc	Abuse deterrent compositions and methods of use
US10207004B2 (en)	2014-04-04	2019-02-19	Douxmatok Ltd	Method for producing sweetener compositions and sweetener compositions
US20160242439A1 (en)	2014-04-04	2016-08-25	Douxmatok Ltd	Method for producing sweetener compositions and sweetener compositions
US10231476B2 (en)	2014-04-04	2019-03-19	Douxmatok Ltd	Sweetener compositions and foods, beverages, and consumable products made thereof
US10729685B2 (en)	2014-09-15	2020-08-04	Ohemo Life Sciences Inc.	Orally administrable compositions and methods of deterring abuse by intranasal administration
WO2022258842A1 (en)	2021-06-11	2022-12-15	Lupin Atlantis Holdings Sa	Extended-release compositions of mexiletine for oral administration

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2881085A (en) *	1953-11-09	1959-04-07	Abbott Lab	Thin film coating for tablets and the like
US2853420A (en) *	1956-01-25	1958-09-23	Lowey Hans	Ethyl cellulose coatings for shaped medicinal preparations
US2887440A (en) *	1957-08-12	1959-05-19	Dow Chemical Co	Enteric coating
BE575775A (de) *	1958-02-18
US2971889A (en) *	1958-03-18	1961-02-14	Smith Kline French Lab	Press coated enteric tablets and process for preparing them
US2928770A (en) *	1958-11-28	1960-03-15	Frank M Bardani	Sustained action pill
US3096248A (en) *	1959-04-06	1963-07-02	Rexall Drug & Chemical Company	Method of making an encapsulated tablet
DE1228757B (de) *	1962-06-28	1966-11-17	Haessle Ab	Verfahren zur Herstellung eines in Wasser und Magensaft rasch zerfallenden UEberzuges auf festen Arzneiformen
US3247066A (en) *	1962-09-12	1966-04-19	Parke Davis & Co	Controlled release dosage form containing water-swellable beadlet
FR1347413A (fr) *	1963-01-29	1963-12-27	Italnysco S P A	Sphérules ou globules à action étalée et procédé pour leur préparation
NL297631A (de) *	1963-06-03
US3539380A (en) *	1968-01-08	1970-11-10	Upjohn Co	Methylcellulose and polyalkylene glycol coating of solid medicinal dosage forms
US3538214A (en) *	1969-04-22	1970-11-03	Merck & Co Inc	Controlled release medicinal tablets
DE2010416B2 (de) *	1970-03-05	1979-03-29	Hoechst Ag, 6000 Frankfurt	Oral anwendbare Arzneiform mit Retardwirkung
GB1468172A (en) *	1973-03-28	1977-03-23	Benzon As Alfred	Oral drug preparations
DE2336218C3 (de) *	1973-07-17	1985-11-14	Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz	Orale Arzneiform
JPS51123814A (en)	1975-04-22	1976-10-28	Shin Etsu Chem Co Ltd	A process for preparing gradually releasable solid medicines
FR2353285A1 (fr) *	1975-09-17	1977-12-30	Doms Laboratoires	Medicament vasodilatateur coronarien perfectionne
FR2377196A1 (fr) *	1977-01-13	1978-08-11	Lipha	Composition medicamenteuse a usage oral
DD146547A5 (de) *	1978-07-15	1981-02-18	Boehringer Sohn Ingelheim	Arzneimittel-retardform mit unloeslichen poroesen diffusionshuellen

1979
- 1979-07-12 DD DD79214300A patent/DD146547A5/de unknown
- 1979-07-13 FI FI792204A patent/FI792204A/fi not_active Application Discontinuation
- 1979-07-13 SE SE7906119A patent/SE7906119L/ not_active Application Discontinuation
- 1979-07-13 BE BE0/196306A patent/BE877706A/fr unknown
- 1979-07-13 IT IT49752/79A patent/IT1116877B/it active
- 1979-07-13 FR FR7918301A patent/FR2430766A1/fr not_active Withdrawn
- 1979-07-13 IL IL57796A patent/IL57796A0/xx unknown
- 1979-07-13 NL NL7905484A patent/NL7905484A/nl not_active Application Discontinuation
- 1979-07-13 GR GR59598A patent/GR71195B/el unknown
- 1979-07-13 GB GB7924504A patent/GB2025227B/en not_active Expired
- 1979-07-13 PT PT69922A patent/PT69922A/de unknown
- 1979-07-13 NO NO792335A patent/NO792335L/no unknown
- 1979-07-13 DK DK296979A patent/DK296979A/da not_active Application Discontinuation
- 1979-07-13 LU LU81503A patent/LU81503A1/de unknown
- 1979-07-13 ZA ZA00793542A patent/ZA793542B/xx unknown
- 1979-07-16 CA CA331,894A patent/CA1126156A/en not_active Expired
- 1979-07-16 AU AU48947/79A patent/AU4894779A/en not_active Abandoned
1981
- 1981-06-15 US US06/273,643 patent/US4361546A/en not_active Expired - Lifetime
1982
- 1982-08-18 US US06/409,131 patent/US4459279A/en not_active Expired - Lifetime
1984
- 1984-04-27 US US06/604,830 patent/US4578264A/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
IT1116877B (it)	1986-02-10
NL7905484A (nl)	1980-01-17
US4578264A (en)	1986-03-25
ZA793542B (en)	1981-03-25
GB2025227B (en)	1982-12-22
BE877706A (fr)	1980-01-14
PT69922A (de)	1979-08-01
IL57796A0 (en)	1979-11-30
US4361546A (en)	1982-11-30
FR2430766A1 (fr)	1980-02-08
AU4894779A (en)	1980-01-24
FI792204A (fi)	1980-01-16
LU81503A1 (de)	1980-08-08
GR71195B (de)	1983-04-11
IT7949752A0 (it)	1979-07-13
DK296979A (da)	1980-01-16
GB2025227A (en)	1980-01-23
US4459279A (en)	1984-07-10
SE7906119L (sv)	1980-01-16
DD146547A5 (de)	1981-02-18
CA1126156A (en)	1982-06-22

Publication	Publication Date	Title
NO792335L (no)	1980-01-16	Legemiddel-retardform med uopploeselige, poroese diffusjonsovertrekk
EP0653935B1 (de)	2002-05-08	Granulierte pharmazeutische zusammensetzung
FI78835C (fi)	1989-10-10	Foerfarande foer framstaellning av en ny dipyridamol-retardform.
AU781058B2 (en)	2005-05-05	Delayed-action form of administration containing tramadol saccharinate
US4957745A (en)	1990-09-18	Pharmaceutical preparation
DK175660B1 (da)	2005-01-10	Farmaceutisk formulering
JPH0530804B2 (de)	1993-05-11
CZ18599A3 (cs)	1999-04-14	Formulace s násobnou jednotkou tramadolu
NO310015B1 (no)	2001-05-07	Preparat med regulert frigjörelse som inneholder et morfinsalt, fremgangsmåte for fremstilling derav, samt anvendelse av preparatet for fremstilling av et medikament
MXPA02002197A (es)	2002-09-02	Formas de administracion farmaceuticas orales con accion retardada.
CZ284382B6 (cs)	1998-11-11	Pevná léková forma s řízeným uvolňováním účinné látky
HU186538B (en)	1985-08-28	Process for producing retarde pharmaceutical compositions containing bromohexine
NZ232030A (en)	1992-03-26	Sustained release pharmaceutical pellet composition; theophylline compound core, coated to allow faster release rate in intestine
KR20090029830A (ko)	2009-03-23	소장 내에서 활성성분의 방출이 제어되는 경구투여용 약제학적 조제물 및 그의 제조방법
CN103417505A (zh)	2013-12-04	具有双相释药行为的石杉碱甲控释制剂及其制备方法
KR102078805B1 (ko)	2020-02-19	토파시티닙을 포함하는 약제학적 조성물
CN101365453A (zh)	2009-02-11	双嘧达莫缓释制剂及其制备方法
CN109789102A (zh)	2019-05-21	包含埃索美拉唑或其药学上可接受的盐的具有改善pH依赖性药物释放特性的制剂
PL192648B1 (pl)	2006-11-30	Preparat farmaceutyczny o kontrolowanym uwalnianiu, zawierający inhibitor ACE jako substancję aktywną
NO312815B1 (no)	2002-07-08	Preparat med kontrollert frigivelse av aktiv substans
CN102764243B (zh)	2014-10-29	一种阿司匹林脉冲释放微丸和其制剂及其制备方法
CN101773482B (zh)	2012-04-25	一种三段式脉冲释药控释片及其制备方法
US20100080846A1 (en)	2010-04-01	Dipyridamole and acetylsalicylic acid formulations and process for preparing same
CN101879139A (zh)	2010-11-10	一种治疗消化性疾病的肠溶制剂及其制备方法
WO2004058228A1 (en)	2004-07-15	Enteric coated fluoxetine composition